SCHEMBL3207210

SCHEMBL3207210

CS(=O)(=O)c1cccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.43
FAAH O00519 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.33
KCNA5 P22460 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
LRRK2 Q5S007 1/20 0.32
ACLY P53396 1/20 0.31
PDE4B Q07343 2/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
CD38 P28907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3204654 0.91 HRH4 (0.33) TAAR1FAAHGPBAR1HRH4ACLY
SCHEMBL3210253 0.86 NR3C1 (0.41) KCNA5HRH4PDE4BPDE4APDE4C
SCHEMBL3129821 0.85 TAAR1 (0.45) TAAR1FAAHLOXL2KCNA5LRRK2
SCHEMBL3211858 0.85 HRH4 (0.40) HRH4PDE4BPDE4APDE4CPDE4D
SCHEMBL3193120 0.85 ACLY (0.33) GPBAR1HRH4ACLYPDE4B
SCHEMBL3194668 0.84 RORC (0.35) HRH4ACLY
SCHEMBL3126626 0.83 TAAR1 (0.44) TAAR1PDE4BPDE4APDE4CPDE4D
SCHEMBL3214943 0.83 HRH4 (0.33) HRH4ACLY
SCHEMBL3202779 0.83 LMNA (0.38) HRH4ACLY
SCHEMBL3202234 0.83 ADRA2A (0.36) HRH4LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B TAAR1 644/4885FAAH 1174/4885LOXL2 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.